(NEW YORK) -- Warren Buffett's decision to undergo radiation therapy for stage 1 prostate cancer has refocused attention on a debate over screening and treating older men for a disease that most often won't kill them.
Prostate cancer specialists worry that because the high-profile, 81-year-old billionaire has chosen two months of daily radiation treatments, other men automatically will "assume that must be the right treatment and it must be good for me," said Dr. Peter Scardino, chairman of the surgery department at Memorial Sloan-Kettering Cancer Center in New York.
"Generally, in a person over 80 years old, you'd be very hesitant to treat a prostate cancer unless it's clearly life-threatening," Scardino said. "Doctors caution men [that] at that age prostate cancer is very common. Most of the time it's not dangerous to their life or health. It's unusual, in our experience, to treat someone over 80, although I've done it."
Of course, no doctor wants to second-guess Buffett's decision, especially without at least two key pieces of information that he didn't disclose when he announced his diagnosis on Tuesday: his PSA score and his Gleason score, both of which help determine whether cancer is low-risk or high-risk, Scardino and other top prostate specialists said.
The PSA test measures levels of prostate specific antigen (PSA), a protein that increases in prostate cancer as well as in benign prostate enlargement.
The Gleason score measures how closely cancer cells resemble normal tissue: The higher the score, the more abnormal the tissue and the more likely it is to spread.
"One would have to know the PSA level and the Gleason grade of the cancer on biopsy to make a proper decision, but the burden would be on the physician to show why immediate treatment is needed for a stage 1 cancer in an 81-year-old man," Scardino said.
Although stage 1 prostate cancer, by definition, hasn't spread beyond the prostate gland, "you could still be stage 1 and have an aggressive tumor," said Dr. Patrick Walsh, a urology professor at Johns Hopkins Medical Institutions in Baltimore who is among the world's top authorities on prostate cancer.
Walsh said one of his own patients, a man whose case had similarities to Buffett's, had his PSA score rise from 2.5 to 8.0 within a year and had a Gleason score of 8 on a scale of 0 to 10, indicating highly abnormal cells.
While readily acknowledging he didn't have important details of Buffett's case, he suggested that "the fact that he is waiting three months to begin radiation suggests to me that he might be going to receive neoadjuvant hormonal therapy and that is consistent with more aggressive disease."
Copyright 2012 ABC News Radio